母亲百日咳免疫的成本效果:动态传播模型对中低收入国家的启示
本研究用动态传播模型评估中低收入国家母亲无细胞百日咳(aP)免疫的成本效果,模型校准于巴西监测数据并调整后用于尼日利亚和孟加拉国。结果显示,婴儿接种覆盖率中等时母亲aP免疫具成本效果,覆盖率低时可节省成本,但覆盖率超过90-95%时不再具成本效果。
要点
- 婴儿疫苗覆盖率中等时,母亲aP免疫具成本效果。
- 婴儿覆盖率低时,母亲aP免疫可能节省成本。
- 婴儿覆盖率超过90-95%时,母亲aP免疫不具成本效果。
核心结论
- 在中低收入国家,婴儿疫苗接种覆盖率中等时母亲aP免疫具成本效果,覆盖率低时可节省成本,覆盖率超过90-95%时不具成本效果。
研究设计与样本
- 开发动态传播模型模拟婴儿全细胞百日咳(wP)疫苗接种加或不加母亲aP免疫的影响,模型校准于巴西监测数据,并调整参数后用于巴西、尼日利亚和孟加拉国。
主要发现
- 在巴西2007年婴儿覆盖率(DTP1 90%,1岁时DTP3 61%)下,母亲免疫每避免一个DALY的成本低于4000美元。
- 模型时间跨度从2030年延长至2100年时,两种婴儿覆盖率下每DALY成本均增加,高覆盖率下增加更陡。
- 结果对贴现率、母亲疫苗价格和母亲aP覆盖率中度敏感,使用100个最佳拟合参数集时结果稳健。
- 低婴儿覆盖率的尼日利亚场景中母亲aP免疫可能节省成本,而高婴儿覆盖率的孟加拉国场景中则非常昂贵。
关键数值与推荐
- 主要成本效果指标为每避免一个伤残调整生命年(DALY)的增量成本(2014年美元)。
- 婴儿疫苗接种覆盖率消除疾病的阈值范围为90-95%,超过此范围母亲aP免疫非常昂贵。
临床怎么用
- 在中低收入国家规划母亲百日咳免疫时,应结合当地婴儿疫苗接种覆盖率评估成本效果,覆盖率中等或偏低时优先考虑。
局限性
- 模型参数调整基于巴西数据并外推至尼日利亚和孟加拉国,可能未完全反映当地流行病学和卫生系统差异。
- 结果对贴现率、母亲疫苗价格和母亲aP覆盖率中度敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study evaluates the cost-effectiveness of maternal acellular pertussis (aP) immunization in low- and middle-income countries using a dynamic transmission model. METHODS: We developed a dynamic transmission model to simulate the impact of infant vaccination with whole-cell pertussis (wP) vaccine with and without maternal aP immunization. The model was calibrated to Brazilian surveillance data and then used to project health outcomes and costs under alternative strategies in Brazil, and, after adjusting model parameter values to reflect their conditions, in Nigeria and Bangladesh. The primary measure of cost-effectiveness is incremental cost (2014 USD) per disability-adjusted life-year (DALY). RESULTS: The dynamic model shows that maternal aP immunization would be cost-effective in Brazil, a middle-income country, under the base-case assumptions, but would be very expensive at infant vaccination coverage in and above the threshold range necessary to eliminate the disease (90-95%). At 2007 infant coverage (DTP1 90%, DTP3 61% at 1 year of age), maternal immunization would cost < $4,000 per DALY averted. At high infant coverage, such as Brazil in 1996 (DTP1 94%, DTP3 74% at 1 year), cost/DALY increases to $1.27 million. When the model's time horizon was extended from 2030 to 2100, cost/DALY increased under both infant coverage levels, but more steeply with high coverage. The results were moderately sensitive to discount rate, maternal vaccine price, and maternal aP coverage and were robust using the 100 best-fitting parameter sets. Scenarios representing low-income countries showed that maternal aP immunization could be cost-saving in countries with low infant coverage, such as Nigeria, but very expensive in countries, such as Bangladesh, with high infant coverage. CONCLUSION: A dynamic model, which captures the herd immunity benefits of pertussis vaccination, shows that, in low- and middle-income countries, maternal aP immunization is cost-effective when infant vaccination coverage is moderate, even cost-saving when it is low, but not cost-effective when coverage levels pass 90-95%.
引用
- Kim SY, Min KD, Jung SM, et al. Cost-effectiveness of maternal pertussis immunization: Implications of a dynamic transmission model for low- and middle-income countries. Vaccine. 2021. PMID: 33303182. doi:10.1016/j.vaccine.2020.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。